Analysts Set Krystal Biotech, Inc. (NASDAQ:KRYS) Price Target at $196.75

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has been assigned an average recommendation of "Buy" from the nine analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $196.75.

Several equities research analysts have recently weighed in on KRYS shares. Stifel Nicolaus upped their price target on Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a research report on Wednesday, September 11th. William Blair raised shares of Krystal Biotech to a "strong-buy" rating in a report on Friday, August 30th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Krystal Biotech in a report on Thursday, August 29th. Evercore ISI increased their price objective on Krystal Biotech from $201.00 to $206.00 and gave the stock an "outperform" rating in a research report on Monday, August 12th. Finally, HC Wainwright boosted their target price on Krystal Biotech from $200.00 to $221.00 and gave the stock a "buy" rating in a research report on Wednesday, August 28th.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 14.10% of the company's stock.

Institutional Trading of Krystal Biotech

A number of institutional investors have recently made changes to their positions in KRYS. Jamison Private Wealth Management Inc. bought a new stake in Krystal Biotech in the 2nd quarter worth $28,000. GAMMA Investing LLC raised its position in Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company's stock valued at $28,000 after purchasing an additional 93 shares during the last quarter. Key Financial Inc bought a new position in Krystal Biotech during the 2nd quarter valued at approximately $28,000. Blue Trust Inc. lifted its holdings in Krystal Biotech by 2,328.6% in the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company's stock worth $30,000 after buying an additional 163 shares during the period. Finally, Quest Partners LLC bought a new stake in shares of Krystal Biotech in the 2nd quarter worth approximately $71,000. Hedge funds and other institutional investors own 86.29% of the company's stock.

Krystal Biotech Trading Up 1.3 %

Shares of NASDAQ KRYS traded up $2.37 during midday trading on Friday, hitting $179.19. The company's stock had a trading volume of 189,815 shares, compared to its average volume of 336,297. The stock has a fifty day moving average price of $186.68 and a 200 day moving average price of $180.05. The firm has a market capitalization of $5.12 billion, a price-to-earnings ratio of 95.82 and a beta of 0.82. Krystal Biotech has a one year low of $93.95 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.53 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The firm had revenue of $70.28 million during the quarter, compared to analyst estimates of $65.27 million. During the same period last year, the company earned ($1.25) earnings per share. The business's revenue for the quarter was up 70283900.0% on a year-over-year basis. On average, equities research analysts predict that Krystal Biotech will post 3.13 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).